CENTRAL TRUST Co Has $2.98 Million Position in Danaher Co. (NYSE:DHR)

CENTRAL TRUST Co lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 26.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 10,709 shares of the conglomerate’s stock after selling 3,901 shares during the period. CENTRAL TRUST Co’s holdings in Danaher were worth $2,977,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC lifted its stake in Danaher by 123.6% in the first quarter. Fifth Third Wealth Advisors LLC now owns 3,584 shares of the conglomerate’s stock valued at $895,000 after buying an additional 1,981 shares during the period. Tsfg LLC boosted its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. Norway Savings Bank grew its holdings in Danaher by 9.6% during the first quarter. Norway Savings Bank now owns 4,832 shares of the conglomerate’s stock valued at $1,207,000 after purchasing an additional 425 shares during the period. Norris Perne & French LLP MI raised its holdings in Danaher by 2.1% in the first quarter. Norris Perne & French LLP MI now owns 78,772 shares of the conglomerate’s stock worth $19,671,000 after purchasing an additional 1,626 shares during the period. Finally, Independence Bank of Kentucky boosted its position in shares of Danaher by 72.1% during the first quarter. Independence Bank of Kentucky now owns 6,498 shares of the conglomerate’s stock worth $1,623,000 after purchasing an additional 2,723 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $247.88 on Friday. The stock has a market capitalization of $183.60 billion, a PE ratio of 42.01, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The stock has a 50 day moving average price of $270.43 and a 200 day moving average price of $260.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period last year, the business earned $2.02 earnings per share. Analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 over the last 90 days. 11.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada dropped their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday. Stifel Nicolaus boosted their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday. Leerink Partners raised their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Finally, KeyCorp upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.